Navigation Links
ResMed VPAP III

ProductsResMed VPAP III
Company ResMed Corp
Item ResMed VPAP III
Features 
  • Uses same device platform as the AutoSet SpiritTM, AutoSet RespondTM and S7TM series of devices for lower inventory, training and labor costs
  • Available with optional integrated humidification
  • VsyncTM algorithm maintains reliable breath triggering and cycling performance to ensure that patients do not feel "out-of-sync with their VPAP, even when normal leaks occur
  • IPAP MaxTM feature offers customizable maximum allowable inspiratory time to protect patients from prolonged inspiratory times related to mask or mouth leak. This helps avoid increased work of breathing and arousals, which means better treatment and fewer patient complaints and callbacks.
  • IPAP MinTM feature helps eliminate shortened inspiratory times often seen in restrictive patients, such as ALS and post-polio patients, and protects them from becoming under- ventilated and waking up gasping for air.
  • Software-controlled, variable-speed motor technology and rise time settings provide more comfortable pressure and flow profiles for better treatment tolerance, resulting in improved patient comfort and compliance with less effort and fewer callbacks.
  • The VPAP III offers a range of tools to meet immediate and long-term data management needs. Both treatment effectiveness and usage data are available on the LCD and with download and viewing in AutoScanTM software.
  • Choice of CPAP and Spontaneous Treatment Modes
Description The VPAP III is a complete system solution for sleep-disordered breathing (SDB), providing comfortable and effective bilevel treatment. The VPAP III is an effective business solution for clinicians, HMEs and sleep labs.
Info ResMed Corp
Customer Service: (800) 424-0737
Web site: http://www.resmed.com/

Related medicine products :

1. ResMed S8 Elite
2. ResMed S7 Elite CPAP
3. ResMed S7™ Lightweight CPAP Device
4. ResMed S8 Escape
5. ResMed AutoSet Spirit
6. ResMed AutoSet Respond
7. ResMed S8 AutoSet Vantage
8. ResMed VPAP III ST
9. ResMed VPAP III ST-A
Measure SpO2 and tcpCO2 with a single sensor.
The TCM400 is the first and only portable instrument to provide up to six simultaneous measurements of transcutaneous oxygen tension (tcpO2)
Two separate sensors provide continuous measurement of tcpO2/tcpCO2 and SpO2.
...versity is the only online source of nationally ac...sts, critical care nurses and other healthcare pro...re available online 24/7, so you can take them at ... and a certificate is issued upon course completio...
Medicine Products:
(Date:12/2/2008)...swire/ -- Today, the University HealthSystem,Cons... has been appointed Vice,President, Quality and P...ing,a year and a half as director of quality and ...al in Chicago, Ill. Previously, she was the senio...area. , "Julie,s experience at Northwestern...
(Date:12/2/2008)...ec. 1 diaDexus, Inc. today,announ...mated format of the,PLAC Test for Lp-PLA2. This a...unning on a wide range of clinical chemistry analy...g Administration (FDA) in December 2007. diaDexus ...d PLAC Test to Europe. , The PLAC Test is t...
(Date:12/2/2008)...onash University, The Brigham and Women,s Hospital...ceuticals has found a new drug with the potential ... shift work. , Dr Shantha Rajaratnam from Monas...d Psychological Medicine said tasimelteon, a drug ...uld be a highly effective treatment for circadian ...
(Date:12/2/2008)...for an Injunction in Federal Court to Reclaim Over...ewswire-USNewswire/ -- Registered nurses for River...al Medical Center, filed a Fair Labor Standards Ac...day to stop the county from violating federal law ...ho are seeking to represent all 867 registered nur...
Breaking Medicine News(10 mins):Health News:Julie Cerese Returns to University HealthSystem Consortium as Vice President of Quality and Patient Safety 2Health News:diaDexus Receives CE Mark Certification for the PLAC(R) Test 2Health News:New medication brings hope of jet lag cure 2Health News:Riverside County Registered Nurses File a Lawsuit to Stop County's Violation of Federal Law 2
... beats per minute (BPM). If the rhythm of the hear...rave danger. This was the case for Jeffrey Nauser....er repeat trips to the Emergency Room where his li...frey’s story began four years ago while on a job i...
...ouch to recover before returning to sports, but an...east not yet. // One Ohio State University Medical...hanical support devices for the heart will be put ...heart to rest and recover itself. Right now, such ...
...nd patients about commonly used thyroid medication...of the drugs, a senior endocrinologist has warned.... University and The Alfred and Epworth Hospitals i...ion (PI) for thyroid medications published in phar...
...search project, titled 'Sun Safe in the Middle Sch...January issue of "Pediatrics”, was undertaken to s...the risks of skin cancer. //The importance of usin...he risk of skin cancer was the keynote of the proj...
Other Medicine News:Health News:Rewiring the Heart 2Health News:Pumps Someday May Allow Patients to Recover Their Own Hearts 2Health News:Pumps Someday May Allow Patients to Recover Their Own Hearts 3Health News:Medicine Information Out of Date 2
(Date:12/1/2008)...OLIS, Dec. 1 Roche announced today...ifferences in perceived pain and,discomfort assoc...blood,glucose monitoring systems and lancing devi...dicated that, overall, the ACCU-CHEK Aviva and ACC...ems and the ACCU-CHEK Multiclix, ACCU-CHEK,Softcl...
(Date:12/1/2008)... MEETING, Pa., Dec. 1 G...ed that dosing of subjects has begun in study MSI-... Phase 1b study of trodusquemine (MSI-1436) in ove...novel therapeutic for the treatment of type 2 diab...rally to regulate insulin and leptin pathways thro...
(Date:12/1/2008)...O, Dec. 1 Vical Incorpor... of a $1.0 million milestone payment from Merck &a...of a Phase I clinical trial of an investigational ...accine is based on Vical,s DNA gene delivery techn...iptase (hTERT). hTERT is the subject of separate l...
(Date:11/28/2008)...OLIS, Nov. 28 Eli Lilly ...lemental New Drug Application (sNDA) from,the U.S...R) (duloxetine HCl),for the management of chronic...,the first half of 2009, adding data from a recent...itis pain of the knee. , The decision does ...
Breaking Medicine Technology:Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Worker ants of the world unite 21 You have nothing to lose but your fertility 5939 1Worker ants of the world unite 21 You have nothing to lose but your fertility 5939 2HMS Presents 4th Annual Heroes of Healthcare Awards 30142 1HMS Presents 4th Annual Heroes of Healthcare Awards 30142 2HMS Presents 4th Annual Heroes of Healthcare Awards 30142 3Compound Tied to Cognitive Deficits in Schizophrenia 30140 1Compound Tied to Cognitive Deficits in Schizophrenia 30140 2Care Improvement Plus Achieves Top Scores for First SNP Evaluation Measures 30137 1Care Improvement Plus Achieves Top Scores for First SNP Evaluation Measures 30137 2
...ontinue Phase II Profiling,in Diabetic Patients ,...ne 2007-Speedel,(SWX: SPPN) today announced that i... development of its family of renin inhibitors wit...f-concept clinical,trial with SPP635 for the treat...lts, the company is to continue developing SPP635 ...
...(BUSINESS WIRE)--Jun 28, 2007,- Progenics Pharmace...cals, a division of Wyeth (NYSE: WYE), today annou...l extension study of,subcutaneous methylnaltrexone...(OIC) in patients with advanced illness. The resul...nal Association of,Supportive Care in Cancer (MASC...
Other Medicine Technology:Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 2Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 3Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 4Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 5Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 6Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 7Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 8Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 2Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 3Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 4Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 5Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 6